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Abstract
Background: Activation of fatty acids by acyl-CoA synthetase enzymes is required for de novo lipid synthesis, fatty acid 
catabolism, and remodeling of biological membranes. Human long-chain acyl-CoA synthetase member 6, ASCL6, is a 
form present in the plasma membrane of cells. Splicing events affecting the amino-terminus and alternative motifs 
near the ATP-binding site generate different isoforms of ACSL6.
Results: Isoforms with different fatty acid Gate-domain motifs have different activity and the form lacking this domain, 
isoform 3, showed no detectable activity. Enzymes truncated of the first 40 residues generate acyl-CoAs at a faster rate 
than the full-length protein. The gating residue, which prevents entry of the fatty acid substrate unless one molecule of 
ATP has already accessed the catalytic site, was identified as a tyrosine for isoform 1 and a phenylalanine for isoform 2 at 
position 319. All isoforms, with or without a fatty acid Gate-domain, as well as recombinant protein truncated of the N-
terminus, can interact to form enzymatic complexes with identical or different isoforms.
Conclusion: The alternative fatty acid Gate-domain motifs are essential determinants for the activity of the human 
ACSL6 isoforms, which appear to act as homodimeric enzyme as well as in complex with other spliced forms. These 
findings provide evidence that the diversity of these enzyme species could produce the variety of acyl-CoA synthetase 
activities that are necessary to generate and repair the hundreds of lipid species present in membranes.
Background
In mammals, long-chain acyl-CoA synthetases (ACSLs)
are necessary for fatty acid degradation, phospholipid
remodeling, and the production of long acyl-CoA esters
that regulate many physiological processes [1]. These
membrane-bound enzymes act on non-polar hydropho-
bic substrates, fatty acids, generating acyl-CoAs, impor-
tant activated intermediates in lipid synthesis pathways,
that are water-soluble as well as powerful detergents [2-
7]. In the first step of the two-step reaction catalyzed by
these enzymes, an acyl-AMP intermediate is formed
from ATP. AMP is then exchanged with co-enzyme A to
produce the activated acyl-CoA. The five long-chain acyl-
CoA synthetase genes can give rise to multiple spliced
transcript variants [1]. The structure of these membrane
proteins has not been solved for the mammalian ACSLs
but homology to a bacterial form, whose structure has
been determined, points at specific structural features
that are important for these enzymes across species
[1,2,8-10]. In particular, the bacterial form acts as a dimer,
and a conserved short motif, called the fatty acid Gate
domain, is implicated in controlling access of the fatty
acid substrate to the catalytic site of each of the two sub-
units [2].
These membrane proteins can not be purified in the
absence of detergent and can form aggregates when over-
expressed in E. coli [1]. Defining the enzymatic character-
istics of the mammalian forms in vivo as well as in vitro
has proven a challenge and has resulted in rather contra-
dictory results [1]. Isoforms of the human ACSL6 mem-
bers, predominately found in brain tissue and
erythrocytes, can be expressed as active enzymes in the
membrane of E. coli [8,11-13]. We determined the activ-
ity of several isoforms representing alternative spliced
variants which differ at their amino-terminus and have
different short motifs of 26 residues in close proximity of
the ATP-binding site [8]. These alternative motifs, spe-
cific for the mammalian forms, were predicted to contain
different versions of the bacterial homologue fatty acid
Gate-domain [2,8,14,15]. We now show that alternative
splicing of these motifs generates isoforms of ACSL6 with
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strikingly different activity, and we identified the aro-
matic residues representing the Gating residue for fatty
acid entry for each version of the Gate-domains of human
ACSL6.
Results and Discussion
Activity of the Tyrosine-Gate, Phenylalanine-Gate and no-
Gate domain isoforms
On the basis of sequence similarity with the Tryptophan-
containing Gate-domain of the bacterial form, we have
proposed that human ACSL6 isoform 1 contains a
Tyrosine-containing Gate-domain (referred to as Y-Gate),
whereas isoform 2 contains a Phenylalanine-containing
Gate-domain (referred to as F-Gate) [1,8]. For isoform 3,
the two alternative spliced exons are skipped and this
enzyme lacks a Gate-domain (referred to as no-Gate)
(Figure 1). Isoform 3 also represents alternative usage of a
splicing site affecting the N-terminus resulting in a short
truncation (Figure 1). These three isoforms and several
recombinant mutant forms were produced in E. coli.
Although a significant amount of the expressed proteins
accumulated in inclusion bodies, mammalian ACSL
forms can be expressed in their active form in the plasma
membrane of E. coli [8,12]. Under the growth conditions
used to produce the recombinant forms, the bacterial
A CS L f orm ,  F a dD [9] , is  e x p r essed a t  a  ve ry l ow leve l
[9,12]. This presents a unique advantage of the bacterial
expression system in contrast to the expression of these
isoforms in eukaryotic cells. In those cells, the endoge-
nous ACSL enzymes would interfere with measurement
of the activity of the recombinant ACSL6 forms. All
forms and mutants used in this study are presented in
Figure 1. Few differences in expression level of the iso-
forms and constructs were observed in the different
membrane fractions obtained from E. coli (Additional file
1, and not shown).
The three versions of the human protein, Y-Gate (iso-
form 1), F-Gate (isoform 2) and no-Gate (isoform 3), have
remarkable different activities (Figure 1 and 2). In pres-
ence of oleic acid (C18:1-OH), formation of oleoyl-CoA
(C18:1-CoA) by the F-Gate enzyme was about 10 times
higher than that of the Y-Gate enzyme (45 ± 2 vs. 5 ± 1
nmol/mg. min) (Figure 1, right column). The activity of
isoform 3, which has no Gate-domain and a short internal
deletion at its N-terminus, was so low that it could not
reliably be distinguished from the activity values obtained
from control membrane fraction isolated from cells that
did not express the human enzyme (0.6 ± 0.4 as com-
pared to the detection limit of ≤0.5 nmol/mg. min) (Fig-
ure 1). In addition, a recombinant full-length version of
an enzyme without a Gate-domain, construct ΔGate, dis-
played no detectable activity (Figure 1). Reactions per-
formed with other fatty acid substrates, palmitic acid
(C16:0-OH) and arachidonic acid (C20:4-OH), did not
result in formation of acyl-CoA products by these two
inactive forms and acyl-AMPs intermediate species were
also not detected (data not shown and see below). These
results established that the fatty acid Gate-domain is
essential for the activity of the human ACSL forms.
Identification of the Gating residues
In the bacterial ACSL protein, the aromatic tryptophan
residue blocks entry of the fatty acid in the absence of
ATP. Upon ATP binding to the nearby P-loop, a confor-
mational change induces rotation of the protruding side-
chain ring of tryptophan away from the center of the fatty
acid channel allowing entry of the fatty acid substrate
[ 2 , 8 ] .  T h i s  t ry p t o p h a n  g a t i n g  r e s i d u e ,  p a r t  o f  t h e  f a t t y
Figure 1 Human ACSL6 isoforms and truncated constructs. A. Car-
toon representation of the three spliced isoforms, and of the four trun-
cated constructs studied in this work. Isoform 1 and 2 represent spliced 
forms with a Gate-domain containing a tyrosine (Y) or a phenylalanine 
(F) at position 319, respectively. Isoform 3 has a short internal deletion 
at the N-terminus, and has no Gate-domain. Numbers on the right of 
each of the construct represent the acyl-CoA synthetase activity rate 
values (nmol acyl-CoA formed per mg proteins per min) obtained with 
oleic acid (6 μM), and the standard deviations of 3 measurements are 
given in parenthesis. Note that for isoform 3 and the two constructs 
ΔGate and ΔN-ΔGate (see text), activity values were as low as the val-
ues obtained with control cells transformed with the empty vector 
alone (values of ≈0.5) and could not be reliably detected (not detected, 
n.d.). B. Amino acids alignment of the N-terminus (top) and of the 
Gate-domain motif (bottom). A predicted trans-membrane spanning 
segment (amino acid 21 to 42) at the N-terminus is indicated for iso-
form 1 and 2. The two predicted aromatic Gating residues, Y319 and 
F319, of the Gate-domains are boxed. Note the presence of H316 in iso-
form 1 and of L316 in isoform 2.
N-ter
ATP-bdg
C-ter  linker Gate
Y
F
Y
F
Isoform:  
1
2
3
Construct:      
∆N-Y-Gate
∆N-F-Gate
∆Gate
∆N-∆Gate
n.d.(≤ 0.5)
50 (±6.0)
90 (±5.0)
45 (±2.0)
5 (±1.0)
                                              N-terminus
1&2 GQFFRSLSATTLVSMGALAAILAYWFTHRPKALQPPCNLLMQSEEVEDS
   3 GQFFRSLSATTL-----------------------------------DS
 ∆N -------------------------FTHRPKALQPPCNLLMQSEEVEDS
                 Gate motif
     1     SQWAPTCADVHISYLPLAHMFERMVQ
     2 KVIFPRQDDVLISFLPLAHMFERVIQ
     3 --------------------------
 ∆Gate --------------------------
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acid Gate-domain, is not conserved in mammalian ACSL.
The two others aromatic residues at position 319,
tyrosine or phenylalanine, were predicted to represent
the gating residues of the two alternative versions of the
human ACSL6 Gate-domain of isoform 1 and 2, respec-
tively [8]. By site-directed mutagenesis, the tyrosine resi-
due of isoform 1 was replaced by phenylanine (Y-to-F
mutant), tryptophan (Y-to-W mutant) or alanine (Y-to-A
mutant). Similarly, the phenylalanine residue of isoform 2
was changed to a tyrosine (F-to-Y mutant), tryptophan
(F-to-W mutant) or alanine (F-to-A mutant). Because the
activity of the Y-Gate isoform was very low, these tests
w e r e  a l s o  p e r f o r m e d  w i t h  t h e  m o r e  a c t i v e  v e r s i o n
obtained by removal of the first 40 residues, ΔN-(Y-Gate)
construct (Figure 1, 2 and Additional file 1). Data
obtained with this truncated form are presented. Substi-
tution of the aromatic residues, tyrosine and phenylala-
nine, to an alanine (Y-to-A and F-to-A mutants)
produced forms with very low activity (Figure 3). This
Figure 2 Acyl-CoA synthetase activity of ACSL6 isoforms. Activity 
rate values (nmol of C18:1-CoA formed/mg of membrane proteins per 
min) of isoform 1 (Y-Gate), isoform 2 (F-Gate) and their respective N-
terminus truncated forms (ΔN-Y-Gate, ΔN-F-Gate) are represented as 
function of the concentration of the substrate oleic acid. For each con-
centration of (14C)-C18:1-OH, rates were obtained by measurements at 
30°C of the formation of C18:1-CoA at 1, 2 and 3 minutes after initiation 
of the reaction with 3 μg of membrane proteins for isoform 1, 1 μg for 
isoform 2 and 0.25 μg for the 2 ΔN-truncated forms. Each value repre-
sents the average of 4 different measurements and the standard devi-
ation is indicated as error bars. Inset top: Activity of isoform 1 was low 
and is shown with a different y axis. Inset bottom: Kinetic parameters 
[Km (μM) and Vmax (nmol/mg.min)] were calculated from these data 
using Prism 5.0 program (see Methods) and are shown in the table.
Figure 3 Role of the aromatic residue at position 319. The tyrosine 
residue of isoform 1 (Y-Gate) was changed by site-directed mutagene-
sis to a phenylalanine (Y to F), a tryptophan (Y to W) and an alanine (Y 
to A). The phenylalanine residue of isoform 2 (F-Gate) was changed to 
a tyrosine (F to Y), a tryptophan (F to W) and an alanine (F to A). Because 
activity of isoform 1 was low, its amino-terminus was removed to in-
crease activity of the mutant forms. Data obtained with ΔN-Y-Gate 
construct and full-length F-Gate isoform are presented. Measurements 
were also performed with the full-length Y-Gate version and con-
firmed findings obtained with the ΔN version. Average and the stan-
dard deviation of 3 different experiments are shown. A. Activity 
obtained with the ΔN-Y-Gate mutants set (left) and with the F-Gate 
mutants set (right) in presence of 5 μM (14C)-C16:0-OH. Left panel: nor-
mal Y-Gate (filled circles); Y319 to W319 (triangles); Y319 to F319 (squares); 
Y319 to A319 (crosses). Right panel: normal F-Gate (filled circles); F319 to 
W319 (triangles); F319 to Y319 (squares); F319 to A319 (crosses). B. Activity 
measurements were performed with 5 μM (14C)-C16:0-OH (open bar), 
(14C)-C18:1-OH (filled bar) or (14C)-C20:4-OH (hatched bar). Activity rates 
were calculated from 0 to 8 minutes (as shown in panel A). The values 
obtained for the normal forms were arbitrary set at 100%, and the ac-
tivity rates of the corresponding mutated Y or F-Gate form, as indicat-
ed, were calculated relative to them.Soupene et al. BMC Biochemistry 2010, 11:18
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effect was independent of the fatty acid chain length (C16,
C18 or C20) and relative saturation or unsaturation (0, 1 or
4 double bonds) (Figure 3, lower panels). Additional evi-
dence of the essential function of these two aromatic resi-
dues was obtained by their substitution by the two other
aromatic residues: Y residue of isoform 1 [ΔN-(Y-Gate)
construct] replaced by F or W, and F residue of isoform 2
replaced by Y or W. For the ΔN-(Y-Gate) protein, substi-
tution of the tyrosine by a phenylalanine (Y-to-F) or tryp-
tophan (Y-to-W) greatly decreased the activity rate of
these mutants (Figure 3, lower left panel). However, in the
context of a F-Gate domain, all three aromatic residues (F,
Y, W) resulted in enzymes with high activity rates (Figure
3, lower right panel).
These results indicate that the splicing event affecting
the two alternative fatty acid Gate-domains of the human
and rodent ACSL6 forms produces enzyme species with
different Gating residues and enzymatic properties. In
addition, these results establish that, for a Y-Gate
enzyme, the presence of a tyrosine residue at position 319
was essential for activity, whereas any aromatic residue
could be tolerated in the F-Gate domain. Finally, the dif-
ference of activity of the Y-to-F mutant compared to a
normal F-Gate enzyme, and of a F-to-Y mutant compared
a normal Y-Gate enzyme indicate that other residues are
involved in defining the specific activity of isoform 1 and
2.
Specific Gate-domain residues essential for activity
Among the 26 residues constituting the two alternative
spliced Gate-domains, the gating residue and 10 addi-
tional residues are different. Thus, a mutant form with a
Y to F change still contains 10 residues present in the Y-
Gate form that are absent in the normal F-Gate form. In
the absence of sufficient structural knowledge on these
domains, we compared the amino acid sequence of the
mammalian, plants and bacterial forms [8] and sought
residues only found, or never found, in combination with
either the tyrosine or the phenylalanine 319. Using this
approach [8], we identified a histidine/leucine residue
pair at position 316 that seemed associated with the
tyrosine/phenylalanine pair at 319 (Figure 1 and 4). As
presented below, whenever a histidine was present at
position 316, enzymes with a tyrosine at position 319
were active, whereas the presence of a histidine was suffi-
cient to inactivate a form with a phenylalanine. Histidine
316 is present in the Y-Gate isoform of ACSL6 and
ACSL1 (the only other ACSL member that can generate
the two versions of the Gate-domain [8]). Histidine 316 is
replaced by a leucine in the F-Gate version (Figure 1) of
both ACSL6 and ACSL1 [8]. As shown in Figure 4, when
a histidine was introduced in place of leucine 316 of the
F-Gate isoform (Lnormal
316  - Fnormal
319  mutated to
Hmutant
316 - Fnormal
319; 3rd bar of graph), the mutant form
had an activity nearly as low as the ΔN-(Y to F)319 mutant
in the Y-Gate environment, i.e. Hnormal
316 - Fmutant
319, 6th
bar. Substituting the phenylalanine of the poorly active
mutant, Hmutant
316 - Fnormal
319 (3rd bar), to a tyrosine, gen-
erated the double mutant enzyme Hmutant
316 - Ymutant
319 in
the context of a F-Gate motif (4th bar) resembling a nor-
mal Y-Gate domain (Hnormal
316 - Ynormal
319, 5th bar), fully
restored activity. Hence, a histidine residue at position
316 cannot be present when a phenylalanine residue is
also present at position 319 (3rd and 6th bars). However, a
Gate-motif with a tyrosine (natural or introduced) can
accommodate both a leucine and a histidine (2nd, 4th, 5th
and 7th bars). Whereas enzymes with a F-Gate domain
can accommodate a tyrosine in place of the phenylalanine
regardless of the residue present at position 316 (2nd and
Figure 4 Residues essential for activity of the two fatty acid Gate-
domains. Leucine 316 of isoform 2 (F-Gate) was changed to a histidine 
in the normal F-Gate form to generate the mutant H316 - F319 and in the 
mutant (F-to-Y)319 to generate the double mutant H316 - Y319. Similarly, 
histidine 316 of isoform 1 (Y-Gate) was changed to a leucine in the nor-
mal Y-Gate form to generate the mutant L316 - Y319, and in the mutant 
(Y to F)319 to generate the double mutant L316 - F319. Activity measure-
ments were performed with 5 μM (14C)-C18:1-OH as described in legend 
of Figure 2. Activity rate of the normal forms (either the F-Gate or the 
Y-Gate; filled bars) was set at 100% and values obtained with the corre-
sponding mutated forms were calculated relative to these. Data ob-
tained with ΔN-Y-Gate construct and full-length F-Gate isoform are 
presented (see legend Figure 3). Average and the standard deviation 
of 3 different experiments are shown.Soupene et al. BMC Biochemistry 2010, 11:18
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4th bars), enzymes with a Y-Gate motif were only active
when a tyrosine was present at position 319 (5th and 7th
bars versus 6th and 8th bar). These results are a strong
indication that other essential residue(s) may be neces-
s a r y  t o  p e r m i t  c o r r e c t  f o l d i n g  a n d / o r  f u n c t i o n  o f  t h i s
domain of the enzyme. In addition to the histidine/leu-
cine pair at position 316, other residues, not necessarily
specific to a Gate motif nor necessarily present in the
Gate-domain, are involved in defining the specific activity
of the isoforms.
ATP requirement and inhibition of activity
As indicated above, isoform 2 carrying an F-Gate domain
was more active than the Y-Gate isoform. The two rat
forms ACSL6_v1 (Y-Gate) and ACSL6_v2 (F-Gate) (≥90%
amino acid identity to the human forms) were also
r e p o r t e d  t o  h a v e  a  d i f f e r e n t  a c t i v i t y  t o w a r d  o l e i c  a c i d
[14]. The rat Y-Gate form had a lower activity than the F-
Gate form, confirming the results obtained with the
human forms, but they also appeared to have a significant
difference of affinity for ATP. Rat ACSL6_v1 (Y-Gate) was
reported to have a remarkable poor affinity for ATP, Km =
12, 210 μM [14], as compared to an already low affinity
(Km = 1, 480 μM) for the F-Gate form [14]. In our system,
the human forms did not show such high ATP require-
ments. Activity rates did not differ significantly at ATP
concentrations of 1, 5 and 20 mM (Figure 5, panel A and
B). Figure 5 shows activity rate values obtained with the
different ATP concentrations relative to value obtained
with 1 mM ATP. Higher concentrations of ATP resulted
in a small increase of activity for the form with a low
activity (Y-Gate) but these concentrations were strongly
inhibitory for the more active F-Gate form and the two
very active N-terminus truncated forms (ΔN-constructs,
see below). Given that inhibition at high ATP concentra-
tion was seen with forms carrying the two versions of the
Gate-domain (F, ΔN-Y and ΔN-F), it seems unlikely that
the lack of inhibition of the lesser active form, Y-Gate,
represents a significant enzymatic difference toward ATP
of the two versions of the Gate-domain, as previously
suggested for the rat ACSL6 isoforms [14].
ATP is needed for the initial formation of the acyl-AMP
intermediate in the two-step reaction catalyzed by ACSL.
CoA-SH is subsequently exchanged to form the final acyl-
CoA product. To determine if excess ATP could inhibit
the CoA-exchange reaction and limit the formation of the
product by the active enzymes, all 14C-labeled com-
pounds present in the reaction mixture were separated,
identified and quantified by thin-layer chromatography
(see Methods section). The distribution of the 14C-
labeled compounds was similar at 1 and 20 mM ATP.
Under these conditions, 70-80% of the substrate was con-
verted and the relative ratio of the two acyl-AMP and
acyl-CoA species was similar, despite a 20-fold difference
in ATP concentration (Figure 5, panel C). However, for
reactions performed at 50 mM ATP, the acyl-AMP and
acyl-CoA species were not formed, and most of the 14C-
label was found in the unreacted acyl substrate (acyl left),
as was the case for the reaction performed without addi-
tion of ATP (0 mM column). Hence, the inhibitory effect
of ATP was also observed on the formation of the inter-
mediary acyl-AMP species and accounted for the
decrease in production of the final acyl-CoA product. As
t h i s  e f f e c t  w a s  n o t  o b s e r v e d  w i t h  a n  e n z y m e  l a c k i n g
strong activity, these results may indicate that the
released pyrophosphate at the first-step and/or the
released AMP during the second step can inhibit the
acyl-AMP reaction. The reported higher Km value for the
lesser active rat ACSL6 isoform 1 may have been errone-
ously determined because of the lack of inhibition and of
the slightly increased activity obtained at high ATP con-
centration, as observed with human isoform 1.
Inhibition of acyl-CoA formation by Triton X-100
The detergent Triton X-100 has been used to solubilize
rodent ACSLs from microsomal membranes at concen-
trations of 16 mM or above. These values far exceed the
critical micellar concentration (CMC≈0.3 mM) and are
therefore expected to produce an assay mixture contain-
ing a significant amount of mixed micellar structures. It
was reported that the activity of different rodent ACSL
forms were either inhibited (ACSL4) [14], stimulated
(ACSL5) [16], or unaffected (ACSL6 isoform 1 and 2) [14]
by Triton X-100 at concentrations above the CMC value.
In our assay system, ACSL6 proteins were not solubilized
from the membrane and only a low amount of Triton X-
100 (70 μM) was added to solubilize the fatty acid sub-
strate. In contrast to the reported results of the rodent
ACSL6, which seemed unaffected by this detergent [14],
the human ACSL6 isoforms [such as the moderately
active isoform 2 and the very active truncated ΔN con-
struct (see below)] were strongly inhibited with an esti-
mated IC50 of 1 mM (Figure 6). To explore this apparent
difference between the human and rodent form, we
treated human isoform 2 with Triton X-100 at an inhibi-
tory concentration of 16 mM, followed by assaying its
activity in the presence of a non-inhibitory concentration
of 0.13 mM. This treatment did not result in decreased
activity (Figure 6, inset), indicating that the detergent
does not denature the protein, at least not irreversibly,
but can decrease the rate of catalysis of the human
ACSL6 enzymes. This concentration dependent inhibi-
tory effect of Triton X-100 on ACSL activity could be the
result of micellar structures that are formed above 0.3
mM. These structures most likely attract the hydrophobic
fatty acid substrate and as such, may compete with the
enzyme, resulting in decreased availability of the sub-
strate. This effect on ACSL6 activity by Triton X-100 sug-Soupene et al. BMC Biochemistry 2010, 11:18
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gests that the conclusions for the different ACSL forms
should be interpreted cautiously and raises concerns for
the usage of this detergent.
Alteration of the Carboxy-terminal domain affects activity
Unexpectedly, an ACSL6 construct with a tag at its C-ter-
minus had a far lower activity than a construct with a tag
fused to its N-terminus. As shown on panel A of Figure 7,
the relative activity rate (normalized to the amount of
ACSL6 protein, as described in the methods section) was
10-times lower for the C-terminally tagged fusion than
for the N-terminally tagged construct. Raw activities data
are presented in Figure 7, panel B. Fusion at either the N-
terminus or C-terminus failed to improve the activity of
isoform 3, supporting previous findings that this enzyme
was not active (Figure 1 and 7, and not shown). The
reduced activity of human ACSL6 (Figure 7) and of
mouse ACSL1 [17,18] suggest that addition of residues to
the short C-terminus hammer domain impair its move-
ment and positioning relative to the anvil central domain,
and thus, in the formation of the catalytic site [2]. In stud-
ies of rat ACSLs, different forms were produced with a
FLAG epitope tag at their C-teminus [14,16,19,20]. Activ-
ities of these recombinant FLAG-enzymes were not com-
pared to N-terminally tagged proteins and our findings
suggest that the kinetic parameters obtained with these
recombinants proteins might not represent those of the
native forms.
Removal of the Amino-terminus stimulates activity
In mammalian cells, the various members of the ACSL
family have been located in membranes of different
organelles [1]. In the host E. coli, human ACSL6 forms are
also associated with the membrane [8,12]. To define
region(s) of the protein responsible for this association,
we removed a motif at the N-terminus of the protein
which was predicted to constitute a trans-membrane
(TM) spanning segment [1,8]. This region partially over-
laps the truncation that naturally occurs in the spliced
variant isoform 3 (Figure 1). Despite this deletion, iso-
form 3 was found in the membrane (Figure 8, panel A,
lane 4). In E. coli, recombinant isoform 1, and isoform 2
truncated of this predicted TM (ΔN constructs) were also
associated with the membrane (Figure 8, panel A, lane 5;
panel B, lane 3 and 6). The ACSL homologue in bacteria,
FadD, has been proposed to associate with the membrane
Figure 5 ATP requirement and detection of acyl-AMP intermediate species. A and B. Activity measurements were performed as described in the 
legend of Figure 2 with the full-length isoforms (open bar) and the respective ΔN-truncated versions (filled bar) of isoform 1 (Y-Gate) (panel A) and 
of isoform 2 (F-Gate) (panel B). Assays were performed in presence of 10 μM (14C)-C18:1-OH and ATP concentrations were 1, 20 and 50 mM, as indicated. 
Relative activity rate values are presented in percent of the rate values obtained in presence of 1 mM of ATP. The actual differences in activity of these 
enzymes are shown in Figure 2. For each ATP concentration value, the average and the standard deviation of 3 to 5 different experiments is shown. 
C. Distribution of (14C)-C18:1-OH (acyl leftover), (14C)-C18:1-AMP (acyl-AMP) and of (14C)-C18:1-CoA (acyl-CoA) present in reactions performed without (0), 
or with addition of 1, 20 and 50 mM ATP, as indicated. Reactions were performed with 10 μM (14C)-C18:1-OH and 1 μg of isoform 2 for 10 minutes at 
30°C. Compounds were spotted on silica plates and separated by thin-layer chromatography. For each radiolabeled compound, the intensity of the 
spot was quantified, and its contribution to the total radiolabeled intensity under each condition was calculated as follows: (14C-species/sum of all 14C 
-species)*100. Note that at 50 mM ATP, the amount of unreacted (14C)-C18:1-OH (acyl leftover) was as high as under condition without addition of ATP 
(0 mM).Soupene et al. BMC Biochemistry 2010, 11:18
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through formation of oligomeric complexes partially
associated with the lipid bilayer. Other hydrophobic
region(s) of human ACSL6 may interact with the bacte-
rial lipids.
The activities of the truncated forms (ΔN constructs)
were assayed with oleic acid (C18:1-OH) and compared to
that of their respective full-length versions (isoform 1 and
2) (Figure 1 and 2). Surprisingly, removal of the N-termi-
nus resulted in enzymes with far greater activity (Figure 2).
These differences were most noticeable in the 10-fold
increase in velocity value of the otherwise poorly active Y-
Gate form. For the more active F-Gate form, removal of the
N-terminus resulted in an increase of the apparent affinity
rather than in the Vmax value. Similarly, large increases in
activity rates were observed with palmitic acid (C16:0-OH)
and arachidonic acid (C20:4-OH) (not shown). As antici-
pated, truncation of the N-terminus did not rescue the
activity of the inactive form truncated of its Gate-domain
(ΔGate and ΔN-ΔGate) (Figure 1, right column).
Amino-terminal domain is not essential for oligomer 
formation
On denaturing polyacrylamide gels, the migration pat-
tern of the truncated F-Gate form was noticeably differ-
ent compare to the full-length protein. As reported
previously [8], when proteins were solubilized from
membranes under mild condition (1% SDS at 37°C)
rather than boiled before separation on gels containing
0.1% SDS, human ACSL6 isoforms were detected as two
bands with apparent molecular mass of 70 kDa and 140
kDa (Figure 8 and Additional file 1). The calculated mass
of a monomeric form was 80 kDa (see legend), but as
commonly observed for hydrophobic proteins, human
ACSL6 migrates faster than the molecular weight stan-
dard of the corresponding mass. The species of higher
molecular mass was twice the apparent mass of a mono-
meric protein and since the two bacterial homologues
(FadD and ttACS) are dimeric enzymes [1,2,4], it likely
represents the dimeric form of human ACSL6. The same
pattern was obtained with rat ACSL6 isoform 1 and iso-
form 2 expressed in E. coli (data not shown). The two
bands (70 and 140 kDa) were also recognized by an anti-
body raised against the epitope tag present at the N-ter-
minus (Additional file 1) and by an affinity-purified
antibody raised against human ACSL6 [8]. Both bands
were also detected in protein extracts of mammalian cells
expressing ACSL6 [8]. Although, these two species were
detected with all forms and recombinant constructs, their
relative amounts were significantly different for the ΔN-
(F-Gate) truncated construct (Figure 8. Panel A, lane 3 vs.
lane 5; Panel B, lane 4 vs. 6). As seen on a gel, the ratio of
high to low molecular mass species was greater for the
truncated ΔN-(F-Gate) protein than for its full-length
version (Figure 8, panels B and C). Hence, the N-terminal
domain is not essential for formation of the dimeric com-
plexes but its removal increased dimer formation and/or
stability in the presence of SDS. Based on the findings
that the bacterial forms act as dimers, these complexes
probably represent the active species of human ACSL6.
Their relative increased in abundance could account for
the higher activity observed with the truncated F-Gate
construct (Figure 2). The ΔN-(Y-Gate) protein was also
more active than its full-length version, but even under
the mild denaturing conditions we used, we could not
detect a difference in the dimer to monomer ratio.
Repeated attempts to resolve and quantify these oligo-
meric forms under non-denaturing conditions [21,22] or
by gel filtration chromatography were not successful. Dif-
ferences in stability of the two full-length forms (isoform
1 versus isoform 2) might also account for their unex-
pected differences of activity (Figure 2).
Detection of interaction between isoforms
To confirm the presence of dimeric complexes, we moni-
tored their formation using a two-hybrid interaction
detection assay. The 3 isoforms and the truncated ΔN
version of isoform 2 were fused to the lambda-cI protein,
Bait constructs, or fused to the amino-terminal domain
of the RNA polymerase alpha subunit, Target constructs
Figure 6 Effect of Triton X-100 on activity. Activity measurements 
were performed with 5 μM (14C)-C18:1-OH as described in legend of 
Figure 2, with isoform 2 (F-Gate) (filled circles) and its N-terminus trun-
cated version, ΔN-(F-Gate) (open circles), in presence of 0.1, 0.5, 1, 2, 3, 
4 and 5 mM Triton X-100. Average and the standard deviation of 3 dif-
ferent experiments performed with each concentration are shown. In-
set: Isoform 2 was incubated 30 min on ice with either buffer or 15.9 
mM (1%) Triton X-100, as indicated. The treated enzyme preparation 
was then diluted in the reactional mixture to lower the concentration 
of Triton X-100 to a non-inhibitory concentration of 130 μM. To the ref-
erence sample incubated with buffer, Triton X-100 was added to the 
reaction at a concentration of 130 μM. Average and the standard devi-
ation of 3 different experiments for each condition is shown.Soupene et al. BMC Biochemistry 2010, 11:18
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Page 8 of 13
(see methods section). In all constructs, fusions were
made at the N-terminus of the ACSL6 isoforms and their
expression was under the control of an inducible pro-
moter (Additional file 2, panel C and Figure 9). In this
system, growth of E. coli in the presence of a histidine
inhibitor (3'-AT) can only be obtained when the two
fusion proteins (Bait and Target) interact to form a
dimeric complex (see methods section). Growth was
monitored under different conditions and tests were per-
formed either on solid media or in liquid culture, in the
absence or presence of the drug, with cells expressing
fusion constructs or lacking the constructs. Results of
these assays are presented in the Additional file 2 and
those obtained on solid media with isoforms 1, 2, 3 and
the ΔN construct cloned in the Bait vector in combina-
tion with either the empty target vector or with isoform 3
cloned in the target vector are shown in Figure 9. Some
combinations of the two vectors with the different iso-
forms resulted in growth defects even in the absence of
the drug (Additional file 2). However, none of the con-
structs with the inactive isoform 3 used as Target showed
a growth defect (Figure 9, top left panel). The cells co-
expressing the same isoform (1/1, 2/2 or 3/3) showed
growth (Additional file 2), confirming existence of the
homodimeric complexes previously detected by electro-
phoresis (Figure 8, panel A, lane 2, 3 and 4). The ΔN trun-
cated construct rescued growth with all 3 isoforms,
providing further evidences that this region is not
Figure 7 Activity of differentially tagged forms in single and dual expression system. Isoform 2 and 3 were cloned in a dual expression vector, 
which allows production of 1 or 2 proteins tagged with unique epitope either at their N-terminus (Nter-isoform) or C-terminus (Cter-isoform). Shown 
are the activity measurements performed with membrane fractions isolated from cells expressing either a single copy of isoform 2 produced with a 
tag at the N-terminus (Nter-2 sample) or at the C-terminus (Cter-2 sample), one copy of isoform 3 (Nter-3), two copies of isoform 2 (Nter-2/Cter-2 sample), 
two copies of isoform 3 (Nter-3/Cter-3 sample), or one copy of isoform 2 and one copy of isoform 3 (Nter-2/Cter-3 sample). Measurements were per-
formed with 5 μM (14C)-C18:1-OH. A. Activity rates were normalized to the amount of N-terminally fused proteins present in the different membrane 
fraction. For the Cter-2 sample, this value was calculated relative to the amount of the ACSL6 enzyme present. The normalized values obtained with 
the sample producing a single protein in its most active version, Nter-2 (1st bar), was arbitrary set at a value of 1 and was used to report the relative 
values obtained with the other samples. B. Shown are the activity rate values relative to the amount of the total proteins present in the different mem-
brane fractions and they represent the raw activity data of the normalized values shown in panel A. Averages and the standard deviations of 3 different 
experiments are shown.
A BSoupene et al. BMC Biochemistry 2010, 11:18
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required for oligomer formation. Heterodimeric interac-
tions were also detected with all forms, especially when
the inactive isoform 3 was used as the target (Figure 9,
compare left and middle 2nd panels, and Additional file 2).
In addition, interactions of the active isoform 1 and 2
with the other forms were detected under both solid and
liquid culture conditions (Additional file 2).
Activity of oligomeric complexes
Addition of a tag at the C-terminus of the active isoform 2
resulted in an enzyme with very low activity. This tagged
version of isoform 2 provided an additional test to detect
the formation of oligomeric complexes. Activity assays
were performed with membrane fractions obtained from
cells carrying a single vector that allowed co-expression
of two differently tagged proteins from the same pro-
moter. This provided an assay for the measurement of the
activity of different isoforms associated in oligomeric
c o m p l e x e s .  F o r  e x a m p l e ,  A C S L  a c t i v i t y  o f  c e l l s  c o -
expressing each of the two tagged versions of isoform 2,
the active Nter-2 with the inactive Cter-2, were compared
to cells that co-express the active Nter-2 with the inactive
Cter-3. In addition, different combinations were made to
generate reference and control cells (Figure 7). To detect
the putative effects of the inactive sub-unit (Cter-2 or Cter-
3) on activity of the enzyme complex (e.g. Nter-2/Cter-2 or
Nter-2/Cter-3), the activity rates were normalized to the
amount of active sub-units present in the complexes, i.e.
Nter-2 (see methods section and Figure 7, panel A). When
the two different tagged versions of isoform 2 (Figure 7,
4th bar) were co-expressed, the rate of formation of acyl-
Figure 8 Detection of isoforms in the membrane of E. coli. ACSL6 
forms were expressed in E. coli. Membrane and soluble fractions were 
obtained as described in the methods section. Proteins were separat-
ed on denaturing SDS-PAGE 7.5% gel and stained with coomassie-
blue. The molecular weight standard is shown on the right. Position of 
the monomer and dimer species is indicated with an arrow. A. Proteins 
present in the membrane (lane 1 to 5) and in the soluble (lane 6 to 9) 
fractions of E. coli carrying the vector and the different isoforms, as in-
dicated, are shown. B. Protein present in membrane fractions of E. coli 
carrying the vector, isoform 1 (Y-Gate), ΔN-(Y-Gate), isoform 2 (F-Gate), 
isoform 3 (no-Gate), ΔN-(F-Gate), ΔGate and, ΔN-ΔGate are shown. C. 
Histogram of the ratios of the intensity value of the slow to the fast mi-
grating bands of isoform 1 and isoform 2 and of their respective N-ter-
minus truncated version (ΔN-Y-Gate and ΔN-F-Gate) is shown. Density 
of bands with molecular mass of ≈75 kDa (monomer) and ≈140 kDa 
(dimer) detected on lane 2, 3, 4 and 6 of the gel shown on panel B were 
quantified using QuantityOne program (Bio-Rad). Intensity values ob-
tained in lane 1 (E. coli proteins only) at the same position on the gel, 
taking into account the slight difference of migration of the different 
bands, were subtracted to the intensity value of each of the bands of 
each of the isoforms and constructs.
Figure 9 Two-hybrid interaction analysis of oligomer formation. 
Isoform 1, 2 and 3 and ΔN-isoform 2 were cloned in the Bait vector (see 
Methods). Isoform 3 was cloned in the Target vector. Results obtained 
with the combination of all isoforms cloned into both vectors as well 
as the complete set of controls cells and conditions are presented in 
Additional file 2. Growth tests were performed on solid media in ab-
sence (non-selective) or presence (selective) of the histidine biosyn-
thesis inhibitor 3'-AT at a concentration of 5 mM. Expression of the 
cloned ACSL6 proteins was placed under the control of an IPTG-induc-
ible promotor and tests were performed without (not induced) or with 
(induced) 30 μM IPTG (see methods). As seen on the control plates and 
as expected, the E. coli cells transformed with empty Bait and Target 
vectors (-/-) grew in absence of the drug but failed to grow in its pres-
ence and, cells transformed with the Bait and Target positive controls 
(+/+; dimerization domain of Gal4 with interacting domain of Gal11) 
grew in presence of the drug only when IPTG (induced condition) was 
present in the medium. Plates on the left side of the figure represent 
the experimental plates with cells transformed with isoform 3 Target 
construct and with one of the 4 different Bait constructs, as indicated. 
Note that, as expected, all cells transformed with the 4 different Bait 
constructs and with the empty Target vector grew in absence of the 
drug but not in its presence.Soupene et al. BMC Biochemistry 2010, 11:18
http://www.biomedcentral.com/1471-2091/11/18
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CoA by membranes obtained from these cells was far
lower than the rate of synthesis obtained with the Nter-2
enzyme expressed alone (1st bar). Even in the absence of
normalization for the relative amount of the active spe-
cies (Figure 7, panel B), activity rate of the Nter-2/Cter-2
enzyme was nearly as low as the value obtained with the
Cter-2 enzyme expressed alone (2nd  b a r )  o r  w i t h  c o -
expression of the two tagged versions of the inactive iso-
form 3 (Nter-3/Cter-3) (Figure 7, last bar). This result
strongly suggests that the inactivated  isoform 2 had a
dominant effect on the activity of the active unit, Nter-iso-
form 2. This effect of one protein on the activity of
another confirmed that oligomeric complexes were
formed as established above. The effect of the inactivated
Cter-isoform 2 on an active form was compared to the
effect of the naturally occurring inactive isoform 3 (the
truncated form that misses the essential Gate-domain) on
that active form. This test may mimic the in vivo circum-
stances in which various spliced isoforms with different
activity rates are expressed in the same cells [1,8]. Intrigu-
ingly, interaction with isoform 3 did not result in inhibi-
tion of the isoform 2. The species Nter-2/Cter-3 (Figure 7,
5th bar) was as active as the homodimer Nter-2 (1st bar).
The C-terminus hammer domain of ACSL is connected
to the anvil domain, carrying the ATP-binding site and
the Gate-domain, by a flexible linker [2]. The hammer
and anvil form the catalytic site and the correct position-
ing of the C-terminus is essential to prevent escape as
well as entry of acyl-AMP until the second step of the
reaction with CoA-SH has occurred, and acyl-CoA is
formed. The defect of the extended C-terminally tagged
enzyme could render the second active sub-unit of the
dimeric complex structurally defective resulting in a
slower acyl-CoA synthetase activity. Isoform 3 lacks the
motif carrying the fatty acid Gate-domain. This domain is
essential for the entry and access of the fatty acid to the
catalytic site. The removal of the short region connecting
the fatty acid tunnel to the ATP-binding site might not
preclude processing of fatty acids once they have found
their way to the site. The apparent activity of the isoform
3 in the complex formed with isoform 2 could indicate
that entry of the fatty acids through one of the sub-units
provides substrate to the other one through an internal
channel event. Efforts to solve the structure of these
homo- and heterodimeric complexes are underway.
Conclusions
The alternative fatty acid Gate-domain motifs play an
essential role in the activity of the human ACSL6
enzymes. The aromatic residues representing the Gating
residues of the two versions of the Gate-domain were
identified as a tyrosine for isoform 1 and a phenylalanine
for isoform 2. A tyrosine and tryptophan could be substi-
tuted to the phenylalanine residue of isoform 2 without
affecting activity whereas the tyrosine residue was essen-
tial for the activity of isoform 1. We also identified
another residue, a leucine, present in the F-containing
Gate domain (F-Gate), that is essential for the activity of
that form. The three isoforms can form dimeric com-
plexes with identical units and with different isoforms. As
previously proposed, the diversity of acyl-CoA synthetase
activities of the many ACSL6 enzyme species might rep-
resent an adaptation mechanism of an enucleated cell, the
red blood cell, to the absolute necessity to repair dam-
aged lipids and to maintain the lipid composition of the
membrane [1,23].
The activation of fatty acids to acyl-CoA is required for
many fatty acid utilizing pathways in physiology. All
plasma membranes need to maintain a defined lipid com-
position, both in relative amount of the different classes
and in molecular species within each class. Acylation of
lysophospholipids with different acyl-CoA species is an
essential step, and ACSL enzymes play a central role in
this process [1]. In the red blood cell membrane, ACSL6
is responsible of maintaining the phospholipid composi-
tion of this enucleated cell lacking de novo lipid synthesis.
For the iron-containing oxygen-carrying red blood cell,
the activities of ACSL6 isoforms are especially important
for the repair of phospholipids damaged by oxidation.
ACSL6 is one of the major forms expressed in neuronal
cells, and as in other cells that rapidly turn-over their
plasma membrane lipids, activities of the different ACSL6
complexes might be essential to their plasma membrane
plasticity [1]. An understanding of how the different iso-
forms of ACSL6 act, and interact, is essential to deter-
mine the mechanisms sustaining the formation of the
various acyl-CoA species needed to maintain plasma
membrane composition. Additional enzymatic studies
combined with structural information are needed to bet-
ter understand the function of these enzymes in physio-
logic processes.
Methods
DNA Manipulations
The cloning of cDNAs of human ACSL6 spliced variant 1,
2 and 3 into the expression vector pET28a (Novagen)
with a hexahistidine tag at the N-terminus, has been pre-
viously published [8]. Removal of the amino-terminus of
isoform 1 and 2 (residues 1 to 42) was performed by PCR
with the set of primers Hs.ACSL6-130/fwd and
Hs.ACSL6-end/rev (Table 1). The two amplicons were
cloned at the NheI and HindIII restriction sites of
pET28a. Compared to the full-length version, the ΔN-
ACSL6_v1 (dubbed ΔN-Y-Gate) and ΔN-ACSL_v2
(dubbed ΔN-F-Gate) constructs lack the first 43 residues,
which removed the trans-membrane spanning segment
predicted at position +21 to 42 [1,8]. Removal of theSoupene et al. BMC Biochemistry 2010, 11:18
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motif carrying the Gate-domain (construct ΔGate) was
performed by PCR. One fragment was amplified from
nucleotides +1 to +915 (1st half) with primers L6-v3-Nhe
with L6-Gate/rev, and a second fragment from +993 to
+2094 (2nd  half) with primers L6-Gate/fwd with Hs-
ACSL6-end/rev. After PCR amplification and purification
from agarose gel, the two amplicons were ligated to each
other using a SalI restriction site generated at the 3' end
and 5' end of the 1st and 2nd fragment, respectively. Trun-
cation of the N-terminus of the ΔGate construct to create
the construct ΔN-ΔGate was performed as described
above.
Site-directed mutagenesis experiments were performed
with the QuikChange Multi Site-directed Mutagenesis kit
(Stratagene) according to the manufacturer instruction.
Primers were designed with the QuikChange®  Primer
Design Program (Stratagene). The presence of the
intended nucleotide change(s) and the absence of unwar-
ranted mutations were verified by full-length sequencing
of the constructs.
Detection of protein-protein interactions was per-
formed in E. coli using the BacterioMatch II Two-hybrid
system (Stratagene). As indicated in Figure 9 and Addi-
tional file 2, the different isoforms were cloned by PCR at
the NotI/BamHI restriction sites of the bait vector (pBT)
and of the target vector (pTRG). Primers were designed
to introduce an EagI and a XhoI site at the 5' and 3' end,
respectively, of the ACSL6 amplicons. Plasmids were
propagated into the E. coli strain XL1-Blue MRF' Kan
(Stratagene). All constructs were verified by sequencing
and expression of the different fusion proteins was veri-
fied by immuno-detection with an affinity-purified anti-
ACSL6 antibodies [8]. Results are presented in Additional
file 2, panel C. Expression of the fused proteins was
induced with a concentration of IPTG of 30 μM. Interac-
tion analysis was performed in E. coli BacterioMatch II
Validation reporter cells, carrying a hisB mutation and
the HIS3 reporter cassette, according to the manufac-
turer instructions (Stratagene).
Co-expression of isoforms fused at their amino-termi-
nus with an hexahistidine-tag, or at their carboxy-termi-
n u s  w i t h  a  S - t a g ,  w e r e  p e r f o r m e d  i n  E. coli cells
transformed with various construct made in the pCOLA-
D U E T  v e c t o r  o f  N o v a g e n .  W i t h  t h i s  v e c t o r ,  t w o  c o n -
structs can be cloned under the control of an identical
promoter and expressed simultaneously upon addition of
IPTG at a concentration of 100 μM in the culture
medium. N-terminally His-tagged constructs were
obtained by PCR cloning at the BamHI and HindIII
restriction sites, whereas C-terminally S-tagged con-
structs were cloned at the NaeI and XhoI restriction sites.
The two primer sets were designed to introduce BamHI
and HindIII sites and PmlI and XhoI sites, respectively.
The two primer sets were Cola-BamH with Cola-Hind,
and Cola-Pml with Cola-Xho. Correct fusion of the dif-
ferent constructs was verified by sequencing, and expres-
sion of the fusion proteins was confirmed by
immuno(affinity)-detection with an anti-Histidine anti-
body (Pierce) and S-protein (Novagen), respectively (see
below).
Expression and immunodetection of ACSL6
ACSL6 isoforms cloned into pET28a and pCOLA-DUET
vectors were transformed into E. coli BL21(DE3) cells
(Novagen). Expression and detection with an HRP-conju-
gated anti-Histidine or anti-ACSL6 antibody were per-
formed as previously described [8]. Cells were disrupted
in breakage buffer containing Tris-HCl 50 mM, pH 8.0,
EDTA 5 mM, NaCl 0.3 M, DTT 5 mM and PMSF 0.1
mM, by two passages in a French press cell at 12,000 psi.
Table 1: List of oligonucleotides used in this study.
Name sequence 5' to 3'
Hs.ACSL6-130/fwd AGCTAGCTTCACTCACCGGCCAAAGGCC
Hs.ACSL6-end/rev GGAAGCTTCACATGGAGATTGAGTAAAGCTCTTC
L6-v3-Nhe ACTATAGCTAGCCAGACACAGGAGATCCTG
L6-Gate/rev AAAGGGTCGACCTCTGTCACTTTCAGAAAGCC
L6-Gate/fwd AAAGGGTCGACTCTGTCGTCTATTGCCACGGAG
Y319W-rev ACATGTGTGCTAAAGGCAACCAGGAAATGTGCA
CATCCGCA
Y319A-rev CATGTGTGCTAAAGGCAAAGCGGAAATGTGCAC
ATCCGCA
Y319F-rev ATGTGTGCTAAAGGCAAAAAGGAAATGTGCACA
TCCG
F319W GATGTGCTCATCTCCTGGCTGCCTCTGGCTCACA
F319A CGATGTGCTCATCTCCGCCCTGCCTCTGGCTCAC
F319Y-rev ATGTGAGCCAGAGGCAGATAGGAGATGAGCAC
ATCG
F/Y-L316H-rev GGCAGATAGGAGATGTGCACATCGTCCTGTC
F-L316H-rev GGCAGGAAGGAGATGTGCACATCGTCCTGTC
Y-H316L CACTTGTGCGGATGTGCTCATTTCCTATTTGCCTT
Y/F-H316L CACTTGTGCGGATGTGCTCATTTCCTTTTTGCCTT
Cola-BamH ACTATAGGATCCGCAGACACAGGAGATCCTGAGG
Cola-Pml ACTATACACGTGCAGACACAGGAGATCCTGAGG
Cola-Hind CTATGCAAGCTTTCACATGGAGATTGAGTAAAGC
Cola-Xho CTATGCCTCGAGCATGGAGATTGAGTAAAGCTC
ACSL6-EagI TACTCGGCCGAGACACAGGAGATCCTGAGG
ΔN-EagI TACTCGGCCGCTCACCGGCCAAAGGCCTTGC
HA-fwd ATGTACCCATACGATGTTCCAGATTACGCTAGAT
HA-rev ATCTAGCGTAATCTGGAACATCGTATGGGTACATSoupene et al. BMC Biochemistry 2010, 11:18
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for The lysate was cleared by centrifugation at 8,000 g for
20 min at 4°C. To prepare the membrane and soluble
fractions, the total extract was subjected to centrifugation
at 100,000 g for 60 min at 10°C. The supernatant repre-
sented the soluble fraction. The pellet represents the
membrane fraction and was suspended in breakage buf-
fer supplemented with 10% glycerol and, stored frozen at
-80°C. Detection of the S-tagged constructs with a HRP-
conjugated-(S-protein) (Novagen) was performed under
the same condition used with the anti-His antibody.
Expression of isoforms cloned in the pBait and pTRG
vectors was performed in M9 salt synthetic medium with
0.2% glucose supplemented with 1 mM MgS04, 1 mM thi-
amine-HCl, 0.2 mM adenine, with 30 μM IPTG (induced
condition), and with 5 mM 3-amino-1,2,4-triazole,
freshly made in DMSO at 1 M, and when appropriate,
supplemented with 25 μg/ml kanamycin, 25 μg/ml
chloramphenicol, and 10 μg/ml tetracycline, according to
the manufacturer instructions (Stratagene). Cells were
grown at 37°C for 24 to 48 hrs or at 30°C for 48 to 72 hrs.
Production of the different fusion proteins was analyzed
by immuno-detection of protein extracts of cells grown in
presence of IPTG with an affinity-purified anti-ACSL6
antibody which recognized all the isoforms and the ΔN
constructs fused to either the lambda-cI protein (Bait
vector set) or the amino-terminal domain of the RNA
polymerase alpha subunit (Additional file 2). The analysis
was done with cells transformed with only one of each of
the constructs so as to confirm that each construct was
correctly fused and produced at level comparable to each
other. Predicted molecular mass (in kDa) of the fusions
were: cI-isoform 1, 103; cI-isoform 2, 103; cI-isoform 3,
95; cI-ΔN-isoform2, 99; RNAPa-isoform 1, 105; RNAPa-
isoform 2, 105; RNAPa-isoform 3, 97.
Acyl-CoA synthetase assay
All measurements were performed with membrane frac-
tions obtained from E. coli BL21(DE3) cells expressing
the different isoforms and constructs. Prior to measure-
ments, control experiments were performed with the dif-
ferent enzyme preparations to determine the correct
amount of proteins that will not process more than 20%
of the radio-labeled fatty acids under the reaction condi-
tion and the period of the incubation. The particular
reaction conditions of each assay are given in the legend
of the figures. In most experiments, 0.25 to 10 μg of pro-
teins were used and the reactions were performed at 30°C
for an incubation period ranging from 0 to 8 min. Unless
indicated otherwise, reactions were performed in a final
volume of 150 μl and initiated by the addition of 130 μl of
a mixture containing the enzyme to the fatty acid dis-
solved in 20 μl. The fatty acid was usually first dispatched
in glass tubes and pre-warmed at 30°C before addition of
the pre-warmed enzyme mixture. When appropriate,
protein diluted in 10 μl was first dispatched in the tubes
and reactions were initiated by addition of 140 μl of the
reaction mixture containing the fatty acids mixture. 14C-
labeled fatty acid suspensions were usually provided at a
concentration of 4 μM (unless otherwise indicated in leg-
end of figures) with a specific activity of 50-54 mCi/
mmol. Dried fatty acids were suspended in 20 μl of 13.5
mM NaHCO3  and 0.55 mM Triton X-100 and were
diluted to 1.8 mM NaHCO3 and 74 μM Triton X-100 in
the final reaction volume. The 130 μl enzyme mixture
was diluted with the fatty acid buffer to a final concentra-
tion of 0.1 M Tris.HCl pH 8.0, 1 mM DTT, 20 mM MgCl2,
20 mM ATP and 0.5 mM CoA. The reaction was stopped
by addition of 2.25 ml of isopropanol/heptane/2 M
H2SO4 (40:10:1, v/v) and vigorous vortexing. Newly syn-
thesized 14C-acyl-CoA was separated from un-esterified
14C-fatty acid by successive addition of 1 ml of heptane
and 1 ml of H2O, and vigorous vortexing. The two phases
were separated by centrifugation at 500 g for 3 min. The
upper organic phase was carefully removed and collected
in a scintillation vial. The lower aqueous phase was then
extracted twice with 2 ml heptane saturated with 4 mg/ml
palmitic acid, and once with 2 ml heptane. Each of the
upper phases were collected and pooled with the first
one. The amounts of newly synthesized 14C-acyl-CoA
and of[14C - f a t t y  a c i d  w e r e  m e a s u r e d  b y  s c i n t i l l a t i o n
counting in the lower and upper phases, respectively. For
each reaction, the total amount of 14C present was calcu-
lated by addition of the dpm values of the upper and
lower phases. Control reactions were performed with
membranes obtained from cells carrying the vector
pET28a and the dpm values obtained were subtracted to
those obtained with the enzyme preparations. For calcu-
lation of the kinetic parameters, data were displayed as a
scatter plot of activity rates in function of the concentra-
tion of substrate (Figure 2) using Prism graphing software
version 5 (GraphPad Software, Inc.), and the kinetic val-
ues were obtained by non-linear regression of the data
computed by the software.
Thin-layer chromatography detection of the acyl-spe-
cies was performed as described in [24]. Reactions were
performed in 15 μl with 10 μM 14C-oleic acid and 1 μg of
membrane proteins. After 10 min incubation at 30°C, the
reaction was stopped with 1.6 μl of acetic acid 50% and
spotted on a silica plate. Along with standards, species
were separated at 4°C for 4-5 hrs in a solvent system
made of 1-butanol/acetic acid glacial/water (80/25/40; v/
v). The plates were dried and analyzed with a Phospho-
Imager Storm Scanner (Molecular Dynamics, GE Health-
care).Soupene et al. BMC Biochemistry 2010, 11:18
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Additional file 1 Immuno-detection of full-length and mutant ACSL6 
proteins. Full-length ACSL6 isoform 2 (F-Gate) and ΔN-truncated version of 
isoform 1 [ΔN-(Y-Gate)] and, their respective mutants obtained by side-
directed mutagenesis of the H/L residue pair at position 316 and of the F/Y 
residue pair at position 319 (see the result section), were expressed in E. coli 
with an hexahistidine tag at their N-terminus. Membrane fractions were 
obtained as described in the methods section. Proteins (10 μg) were sepa-
rated on denaturing SDS-PAGE 7.5% gel and stained with an HRP conju-
gated anti-histidine antibody (India-His, Pierce). The molecular weight 
standard (Dual Precision Plus protein, Bio-Rad) is indicated on the left. Posi-
tion of the monomer and dimer species is indicated by arrow on the right. 
Some extra bands, that may represent partially denatured oligomeric com-
plex and aggregates (bands between the dimer and monomer bands) and 
unfinished translated products (detected by mean of the hexahistidine tag 
present at their N-terminus) as well as degradation products, can be seen 
and are indicated with asterisk.
Additional file 2 Two-hybrid interaction analysis of oligomer forma-
tion. Isoform 1, 2 and 3 were cloned in Bait and Target vectors. The trun-
cated ΔN form of isoform 2 was cloned in the Bait vector. Including the 
empty vectors, all the different plasmid combinations were transformed in 
the hisB-derivatived E. coli strain carrying the reporter HIS3 cassette. A. 
Growth tests were performed on solid media in absence (not induced) or 
presence (induced) of 30 μM IPTG and without or with addition of 5 mM 3'-
AT (drug). E. coli strain transformed with the two vectors (-/-) grew in 
absence but not in presence of the drug; positive control (+/+; Gal4/Gal11) 
grew in presence of the drug and IPTG. Plates on the left side represent cells 
transformed with the 4 Bait constructs, as indicated on the top of each col-
umns, and with the 3 Target constructs, as indicated on the left side. Note 
that some combinations resulted in poor growth. B. Growth tests were per-
formed in liquid media in presence of the 30 μM IPTG without or with 5 mM 
3'-AT, at 37°C. The histogram represent the ratio of the growth yield values 
of the cultures (OD600nm) with and without 3'-AT obtained with each of the 
different combination of constructs (as seen on panel A). Bait and target 
constructs combinations are indicated on the left of each column of the 
histogram. C. Production of the different fusion proteins was analyzed by 
immuno-detection, as described in the Methods section.
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